Thursday, March 18, 2004

From Health Canada:
ZYPREXA* (olanzapine) and Cerebrovascular Adverse Events in Placebo-Controlled Elderly Dementia Trials
Eli Lilly Canada Inc., following discussions with Health Canada, would like to inform you of important new safety information pertaining to cerebrovascular adverse events, that have occurred in elderly patients with dementia-related psychosis treated with ZYPREXA (olanzapine) in clinical trials. ZYPREXA is not approved for use in elderly patients with dementia-related psychosis.

No comments: